Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Amazing Sales of Paxlovid (CBS News).
"These medicines have a sweet spot. If the day you get diagnosed COVID you say 'forget it, I'll be fine,' and then...
Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
Tax Loss Selling Bargain? Adding Aditxt (ADTX).
Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Mitesco (MITI) Sets Opening Dates for New Minneapolis Clinics, Additional Sites in Minneapolis and...
MINNEAPOLIS, MN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTCQB:MITI) ("Mitesco" or the "Company"), a leading operator of wellness clinics...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Aphex BioCleanse (SNST) Making Serious Headlines.
Relatively quiet for most of the year. Aphex BioCleanse, our favorite Super Bug sanitizer company, made two back-to-back announcements - signaling things...
Latest article
Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq. (WSJ)
Investor-protection advocates say many belong to risky small companies that should be on the OTC market.
With 557 names...
Selling Under Cash. LQR House (LQR) Addresses Nasdaq Delisting.
If You're a Sophisticated Speculator, and we do Mean Sophisticated, Study LQR House (LQR) or 'the Liquor House' Story.
LQR House (LQR). And the Numbers are In!
A Situation Which Can't be Ignored!
That's not to say run out and buy it, but this current valuation...
